← FDA DRUG APPROVALS

FDA ANDA · ANDA213986

POTASSIUM CITRATE

Sponsor: TORRENT

APPLICATION
ANDA213986
TYPE
ANDA
ORIGINAL APPROVAL
2024-02-06
LATEST ACTION
2024-02-06
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

POTASSIUM CITRATEDiscontinued
POTASSIUM CITRATE 15MEQ · TABLET, EXTENDED RELEASE · ORAL
POTASSIUM CITRATEDiscontinued
POTASSIUM CITRATE 5MEQ · TABLET, EXTENDED RELEASE · ORAL
POTASSIUM CITRATEDiscontinued
POTASSIUM CITRATE 10MEQ · TABLET, EXTENDED RELEASE · ORAL

Approval history

2024-02-06UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →